Table 1 Clinical trials in the context of MTAP. Data collected from clinicaltrials.gov on 14th May 2022
From: MTAP loss: a possible therapeutic approach for glioblastoma
Inhibitor / Drug | Condition(s) | Sponsor | ClinicalTrials.gov Identifier | Phase | First Posted (Year) | Recruitment Status |
|---|---|---|---|---|---|---|
AG-270 | Advanced Solid Tumors Lymphoma | Institut de Recherches Internationales Servier | NCT03435250 | Phase 1 | 2018 | On-going |
IDE397 | Solid tumor | Ideaya Biosciences | NCT04794699 | Phase 1 | 2021 | On-going |
GSK3368715 | Neoplasms | GlaxoSmithKline | NCT03666988 | Phase 1 | 2018 | Completed |
PRT811 | Advanced Solid Tumor Recurrent Glioma | Prelude Therapeutics | NCT04089449 | Phase 1 | 2019 | Recruiting |
AMG 193 Docetaxel | Advanced MTAP-null Solid Tumors | Amgen | NCT05094336 | Phase 1 Phase 2 | 2021 | Not started |
TNG908 | MTAP-deleted solid tumors | NEXT Oncology | NCT05275478 | Phase 1 | 2022 | Recruiting |
MRTX1719 | MTAP deleted solid tumors | Mirati Therapeutics Inc. | NCT05245500 | Phase 1| Phase2 | 2022 | Recruiting |
Pemetrexed | Chordoma | Saint John’s Cancer Institute | NCT03955042 | Phase 1 | 2019 | On-going |
Pemetrexed Avelumab | Urothelial cancer MTAP negative | M.D. Anderson Cancer Center | NCT03744793 | Phase 2 | 2018 | On-going |
Pemetrexed Zimberelimab Etrumadenant | Previously Treated Advanced or Metastatic MTAP Deficient Urothelial Carcinoma | M.D. Anderson Cancer Center | NCT05335941 | Phase 2 | 2022 | Not yet recruiting |
L-alanosine | Lung Cancer Malignant Mesothelioma Pancreatic Cancer Sarcoma | National Cancer Institute (NCI) | NCT00062283 | Phase 2 | 2003 | Completed |
L-alanosine | Brain and Central Nervous System Tumors | National Cancer Institute (NCI) | NCT00075894 | Phase 1 | 2004 | Completed |
Pre-screening study | Advanced Solid Tumors Lymphoma | Agios Pharmaceuticals | NCT03361358 | N/A | 2017 | Completed |